Key Stats for International Business Machines Corporation Stock
- Past-Week Performance: -4.9%
- 52-Week Range: $214.5 to $324.9
- Current Price: $251.6
What Happened?
Completing its $11 billion all-cash acquisition of Confluent on March 17, International Business Machines Corporation (IBM) closed the final piece of a software-led platform strategy that has lifted free cash flow from roughly $12.7 billion in 2022 to $14.7 billion in 2025, the highest margin in the company’s 114-year reported history, even as shares at $251.60 sit 27% below their November record of $324.90.
IBM’s Q4 2025 earnings, reported January 28, provided the clearest proof yet of the model’s durability: total revenue grew 9%, software accelerated to 11% growth, and IBM Z mainframe revenue surged 61% year-over-year, delivering the segment’s highest fourth-quarter revenue in more than two decades.
Software annual recurring revenue, the forward-looking indicator of subscription revenue locked under contract, reached $23.6 billion exiting 2025, up more than $2 billion year-over-year, while OpenShift, IBM’s container platform for running enterprise applications across hybrid cloud environments, grew past $1.9 billion ARR at a 30%-plus rate, a figure that trails only hyperscaler-native offerings in the category.
CFO Jim Kavanaugh stated on the Q4 2025 earnings call that “we’ve grown free cash flow $5.5 billion” over the prior three years, a trajectory he tied directly to software mix expansion and the $5.5 billion annual productivity run-rate target IBM now expects to reach by year-end 2026.
IBM’s competitive position in the next three to five years rests on three converging bets: Confluent’s real-time data streaming layer accelerating the $12.5 billion cumulative GenAI book of business, an expanded NVIDIA partnership bringing Blackwell Ultra GPUs to IBM Cloud in early Q2 2026, and a quantum computing program on track for fault-tolerant systems by 2029, all supported by a 2026 free cash flow target of $15.7 billion that management says they intend to beat.
Wall Street’s Take on IBM Stock
Confluent’s March 17 close adds the real-time data streaming layer IBM needed to make its hybrid AI platform complete, converting a $12.5 billion cumulative GenAI book of business from a consulting-heavy bet into an integrated software stack with recurring revenue underneath it.
IBM’s estimates projects revenue growing from $67.5 billion in 2025 to $71.2 billion in 2026 at 5.4% growth, supported by IBM’s own guidance of 10% software growth and the Confluent contribution expected to close mid-cycle, giving the top line a second-half acceleration not fully priced at current levels.
Normalized EPS of $11.59 in 2025 is forecast to reach $12.37 in 2026 and $17.81 by 2030, a trajectory built on EBITDA margin expanding from 28.4% to 32.1% over that period as software, now 45% of revenue and approximately two-thirds of profit, continues to crowd out lower-margin consulting and infrastructure revenue.
Ten analysts rate IBM a buy or outperform against eight holds and two sells, with a mean price target of $313.03 across 18 estimates, implying 24.4% upside from $251.60 as the street prices in software acceleration and Confluent synergies but not yet the full FCF compounding effect.
The analyst price target range spans $218 on the low end to $390 on the high, with the bear case anchored to Confluent dilution of ~$600 million pressuring 2026 earnings and the bull case contingent on OpenShift ARR sustaining its 30%-plus growth rate and Confluent reaching EBITDA accretion in its first full year post-close.
What Does the Valuation Model Say?
The TIKR mid-case targets $339.28 by December 31, 2030, built on a 4.9% revenue CAGR and 16.7% net income margin, both supported by IBM’s own 10% software growth guidance and Confluent’s day-one ARR contribution to the $23.6 billion recurring revenue base.
Meanwhile, the TIKR estimate of 5.1% EPS CAGR through 2030 is conservative against IBM’s actual 12.2% normalized EPS growth in 2025, suggesting the mid-case $339.28 target has meaningful upside if software sustains double-digit expansion.
CEO Arvind Krishna’s commitment to $5.5 billion in annual productivity run-rate savings by year-end 2026 signals that margin expansion is operational, not aspirational, already visible in the 170 basis points of operating gross profit margin expansion delivered in 2025.
The model breaks if Confluent EBITDA accretion slips past year one, because the $600 million 2026 dilution then compounds into 2027 without the offsetting revenue synergy, pressuring the FCF trajectory that anchors the $339.28 target.
IBM’s Q2 2026 earnings will be the first read on whether Confluent integration is tracking, specifically whether software ARR inflects above $23.6 billion on an accelerating trajectory consistent with the 2030 FCF margin target of 28.7%.
Should You Invest in International Business Machines Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IBM stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track International Business Machines Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze X stock on TIKR for Free →
